This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
CCXI Overzicht aandelen
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 5/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
ChemoCentryx, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$51.99 |
| 52 Week Hoogtepunt | US$52.00 |
| 52 Week Laag | US$14.95 |
| Bèta | 1.23 |
| 11 maand verandering | 0.41% |
| 3 maanden verandering | 134.51% |
| 1 Jaar Verandering | 50.39% |
| 33 jaar verandering | 558.10% |
| 5 jaar verandering | 642.71% |
| Verandering sinds IPO | 372.64% |
Recent nieuws en updates
ChemoCentryx shareholders approve $4.7B merger with Amgen
Oct 18ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
Aug 09Recent updates
ChemoCentryx shareholders approve $4.7B merger with Amgen
Oct 18ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
Aug 09ChemoCentryx: Revisiting The Investment Case
Jun 21ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Jun 06
ChemoCentryx: Good Post-Approval Performance, But Needs More Time
Mar 03ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Feb 11Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week
Jan 21Checking In On ChemoCentryx
Dec 15Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?
Oct 09ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way
Sep 29ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends
Aug 24Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook
Aug 11ChemoCentryx: CRL Less Likely
Jul 25ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price
Jul 11ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jun 15ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress
Jun 08ChemoCentryx: CRL Likely
May 09ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action
May 07Chemocentryx shares plunge 47% as FDA report identifies concerns with vasculitis candidate
May 04When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?
Mar 03ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 04
ChemoCentryx: Great Drug, Good Prospects, Uncomfortable Stock Price
Jan 14Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?
Dec 31Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)
Dec 23ChemoCentryx's avacopan flunks mid-stage study in rare kidney disease study
Dec 21Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?
Dec 13Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?
Nov 22ChemoCentryx, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 10Rendement voor aandeelhouders
| CCXI | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 0.1% | -0.5% | 0.4% |
| 1Y | 50.4% | 18.3% | 32.6% |
Rendement versus industrie: CCXI exceeded the US Biotechs industry which returned -1.9% over the past year.
Rendement versus markt: CCXI exceeded the US Market which returned -19.8% over the past year.
Prijsvolatiliteit
| CCXI volatility | |
|---|---|
| CCXI Average Weekly Movement | 31.3% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: CCXI's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: CCXI's weekly volatility has increased from 18% to 31% over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1996 | 178 | n/a | www.chemocentryx.com |
ChemoCentryx, Inc. Samenvatting
| CCXI fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$3.74b |
| Inkomsten(TTM) | -US$133.09m |
| Inkomsten(TTM) | US$37.28m |
100.3x
P/S-verhouding-28.1x
Koers/WinstverhoudingIs CCXI overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CCXI resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$37.28m |
| Kosten van inkomsten | US$71.86m |
| Brutowinst | -US$34.58m |
| Overige uitgaven | US$98.51m |
| Inkomsten | -US$133.09m |
Laatst gerapporteerde inkomsten
Jun 30, 2022
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -1.85 |
| Brutomarge | -92.76% |
| Nettowinstmarge | -357.01% |
| Schuld/Eigen Vermogen Verhouding | 10.5% |
Hoe presteerde CCXI op de lange termijn?
Bekijk historische prestaties en vergelijking